OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 1.

Antifungal susceptibility of the Lichtheimia ornata isolate from this study and previously reported Lichtheimia spp. and their clinical information

Antifungal agent Time (hrs) assessed MIC or MEC* (μg/mL) for:
L. ornata (this study) L. ornata, previously reported in rhinocerebral mucormycosis [4] L. ornata, previously reported [9]
Amphotericin B 24/48 2/4 2/NA 0.12/0.12
Anidulafungin 24/48 4/>8 4/32
Micafungin 24/48 >8/>8 >256/NA 32/32
Caspofungin 24/48 >8/>8 >16/NA 32/32
5-flucytosine 24/48 >64/>64 >64/NA
Posaconazole 24/48 1/1 2/NA 0.25/0.25
Voriconazole 24/48 >8/>8 >16/NA 16/16
Itraconazole 24/48 0.5/1 1/NA 0.5/1
Fluconazole 24/48 >256/>256 >64/NA
Clinical information L. ornata (this study) L. ornata, previously reported in rhinocerebral mucormycosis [4] L. ornata, previously reported [9]
Age (yr)/sex 67/F 40/F NA
Organ involvement Lungs Rhino-orbital-cerebral region NA
Underlying condition Acute lymphoblastic leukemia Aplastic anemia, after allogeneic hematopoietic stem cell transplantation NA
Diagnosis Pulmonary mucormycosis Rhinocerebral mucormycosis NA
Treatment Liposomal amphotericin B Amphotericin B NA
Outcome Cured Died NA

*Cut-off values for echinocandins (anidulafungin, micafungin and caspofungin) are interpreted as minimal effective concentration instead of minimal inhibitory concentration [7].

Abbreviations: MIC, minimal inhibitory concentration; MEC, minimal effective concentration (calculated for echinocandins); NA, not available; F, female.

Ann Lab Med 2024;44:371~374 https://doi.org/10.3343/alm.2023.0426

© Ann Lab Med